Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703538 | 1.00 | MEN1 (0.52) | MEN1KMT2AKCNH2ALDH1A1NPC1 | |
| SCHEMBL6703540 | 1.00 | MEN1 (0.52) | MEN1KMT2AKCNH2ALDH1A1NPC1 | |
| SCHEMBL6704090 | 0.79 | KCNH2 (0.43) | MEN1KMT2AKCNH2ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL6705109 | 0.78 | KMT2A (0.59) | MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL6703672 | 0.76 | PGR (0.38) | KCNH2 | |
| SCHEMBL6703666 | 0.76 | PGR (0.38) | KCNH2 | |
| SCHEMBL6703669 | 0.76 | PGR (0.38) | KCNH2 | |
| Hydrochloric Acid SCHEMBL6705114 | 0.76 | KMT2A (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3896913 | 0.75 | KCNH2 (0.64) | KMT2AKCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6272105 | 0.75 | KCNH2 (0.64) | KMT2AKCNH2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-5998447-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT AG (DE) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | MEN1 4547/4885KMT2A 2615/4885KCNH2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.